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Background and purpose — Orthopedic surgery is one 
of the specialties with most compensation claims, therefore 
we assessed the most common reasons for complaints fol-
lowing total hip arthroplasty (THA) reported to the Nor-
wegian System of Patient Injury Compensation (NPE) and 
viewed these complaints in light of the data from the Norwe-
gian Arthroplasty Register (NAR).
Patients and methods — We collected data from NPE 
and NAR for the study period (2008–2018), including age, 
sex, and type of complaint, and reason for accepted claims 
from NPE, and the number of arthroplasty surgeries from 
NAR. The institutions were grouped by quartiles into quar-
ters according to annual procedure volume, and the effect 
of hospital procedure volume on the risk for accepted claim 
was estimated.
Results — 70,327 THAs were reported to NAR. NPE 
handled 1,350 claims, corresponding to 1.9% of all reported 
THAs. 595 (44%) claims were accepted, representing 0.8% 
of all THAs. Hospital-acquired infection was the most 
common reason for accepted claims (34%), followed by 
wrong implant position in 11% of patients. Low annual 
volume institutions (less than 93 THAs per year) had a sta-
tistically significant 1.6 times higher proportion of accepted 
claims compared with higher volume institutions.
Interpretation — The 0.8% risk of accepted claims fol-
lowing THAs is 1.6 times higher for patients treated in low-
volume institutions, which should consider increasing the 
volume of THAs or referring these patients to higher volume 
institutions.
In Norway, compensation claims are handled by the Norwe-
gian System of Patient Injury Compensation (NPE) and not 
by the judiciary system. If a patient in Norway suffers a com-
plication due to a treatment error, within either the public or 
private healthcare sector, the patient can file a free-of-charge 
compensation claim to NPE. For claims to be accepted, 3 cri-
teria must be met. 1st, the injury must have occurred during 
medical treatment (examination, diagnosis, or treatment/lack 
of treatment) or during follow-up, and the treatment must be 
deemed substandard or erroneous based on current treatment 
guidelines. 2nd, the injury must have led to financial loss (cur-
rently set at €1,000) or to a persistent medical impairment of 
minimum 15%. Lastly, the claim must be filed within 3 years 
after the patient became aware that the injury was likely a 
treatment error. There is 1 exception clause to these criteria: 
If the injury is rare and severe, claims may be accepted even 
when no treatment error has been identified. The amount of 
compensation is being reviewed on an individual basis and 
calculated to cover the patient’s loss of income and increased 
medical expenses due to the treatment injury.
Orthopedic surgery is one of the specialties with most com-
pensation claims following medical treatment (Jena et al. 
2011). Previous studies on compensation claims after THAs 
have been limited by methodological inadequacies, such as 
short study period or limited sample size with claims rang-
ing from 40 to just above 300 (Bhutta et al. 2011, Bokshan 
et al. 2017, Novi et al. 2020). We evaluated claims following 
both primary and revision THAs filed at the NPE from 2008 to 
2018 and compared these findings with data from NAR, with a 
focus on institutional procedure volume. 
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Patients and methods
Patients
All patients of any age who filed a claim with NPE following 
primary or revision THA from 2008 to 2018 were included. 
Patients who underwent primary hemiarthroplasty or THA for 
a femoral neck fracture were excluded. 
Methods
The Norwegian Arthroplasty Register (NAR) was founded 
in 1987, with aims to monitor the safety and epidemiology 
of total joint arthroplasties (Havelin et al. 2000). Annually, 
approximately 98% of primary THAs and 93% of revision 
THAs are reported to NAR (NAR 2020).
Data from NAR was collected for the study period (2008 
through 2018). The data was stratified by the number of 
arthroplasty procedures performed every year per institution. 
The institutions were then divided by quartiles into quarters 
according to annual procedure volume groups: Quarter 1 (Q1) 
consisted of 7 institutions with an annual volume of less than 
93 hip arthroplasties. Quarter 2 (Q2) included 8 institutions 
that performed 93–263 procedures per year. The third quarter 
(Q3) comprised 8 institutions with an annual surgical volume 
of 264–466 hips, and, finally, the highest volume quarter (Q4) 
included 7 institutions that perform more than 466 hip arthro-
plasties yearly.
All claims filed at the NPE following THA in the study 
period were collected, both primary THA and revision THA. 
The data was stratified by institution, the patient’s age and 
sex, type of complication, any reoperations, and any fatalities. 
The reasons for the claims were recorded, together with the 
decision made by NPE (accepted or rejected claims). When 
evaluating the outcome of claims on institutional volume, the 
outcome of interest was the proportion of procedures result-
ing in an accepted claim, with the individual institution as the 
analysis unit.
Statistics
Continuous variables were described by mean (SD) or median 
(range) while categorical data were presented in frequencies. 
Groups were compared using the chi-square test. The insti-
tutions by procedure volume were compared using ANOVA 
after asserting conditions were met, and p-values adjusted for 
multiple testing by Tukey’s comparison test. Between-quarter 
associations were quantified by odds ratio. A p-value < 0.05 
was considered statistically significant. The data was analyzed 
using IBM SPSS version 26 (IBM Corp, Armonk, NY, USA).
Ethics, funding, and conflicts of interest
The Regional Ethical Committee deemed approval not neces-
sary as all data is based on already anonymized records (REK 
15.10.10). The study was funded by research grants from the 
Norwegian Research Council (the Norwegian Cartilage Proj-
ect, grant number 2015107). The authors declare no conflict 
of interests. 
Results 
During the study period from 2008 to 2018 (11 years) 70,327 
hip arthroplasties were reported to NAR, of which 86% were 
primary procedures and 14% were revision THAs. During 
this period, NPE received 53,000 claims, of which 31% were 
related to orthopedic surgery and 1,350 claims were filed fol-
lowing hip arthroplasties, representing 1.9% of all hip proce-
dures reported to NAR. Patients filing a claim with NPE were 
younger than the average age of patients reported to NAR (64 
years, SD 12) compared with 68 (SD 11) years, p < 0.001). 
NAR received reports on 65% of women, which was compa-
rable to the 67% of claims that were put forward by women (p 
= 0.2) (Table 1). 
595 (44%) of 1,350 claims were accepted, representing 0.8% 
of all hip arthroplasties reported to NAR in the study period. 
549 claims were accepted following primary procedures (0.9% 
of all primary hip arthroplasties) and 46 claims were accepted 
after revision THA (0.5% of all revisions) (p < 0.001).
Hospital-acquired infection was the most common reason 
for accepted claims (34%), followed by wrong implant posi-
tion (11%) (Table 2). There was a decline in claims due to 
abductor deficiency towards the end of the period, with 67 
claims (10 granted) between 2011 and 2014 compared with 
20 claims (4 granted) during 2015–2018 (p = 0.04).
17 of 23 claims from private hospitals were accepted, com-
pared with 578 of 1,327 claims from public hospitals (p = 
0.004).
5 claims involving fatalities were filed, all occurring in male 
patients, and all 5 claims were accepted. 3 patients aged 63, 
66, and 88 succumbed to complications related to surgical 
site infection following a primary THA. A 67-year-old patient 
with known diabetes mellitus underwent revision surgery and 
died due to hypoglycemia as blood glucose was not followed 
up according to guidelines. A 52-year-old patient suffered a 
Table 1. Demography of hip arthroplasty procedures reported to the 
Norwegian Arthroplasty Registry (NAR) and claims due to treatment 
injuries following hip arthroplasties filed with the Norwegian System 
of Patient Injury Compensation (NPE) during 2008–2018
 Hip 
 procedures Compensation Accepted Rejected
 reported claims filed claims claims
 to NAR to NPE n = 595 n = 755  
Factor n = 70,327 n = 1,350 (44%) (56%)
Age, mean (SD) 68 (11) 64 (11) 64 (11) 64 (12)
 range 11–100 20–89 21–89 20–89
Females, n (%) 45,572 (65) 899 (67) 348 (59) 551 (73)
SD, standard deviation.
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pulmonary embolus following a primary THA despite pro-
phylactic administration of low-molecular-weight heparin. No 
treatment error was identified in that case, but compensation 
was granted based on the exception clause. 
At the time of writing [August, 2020], 90% of accepted 
claims have had the compensation calculated, amounting to 
€15.4 million that has been paid out in compensation follow-
ing hip arthroplasties performed during the period 2008–2018, 
with average compensation of €26,000.
Institutional procedure volume
Institutions with the lowest annual volume (< 93, Q1) had a 
statistically significant higher fraction of accepted claims per 
procedure compared with higher volume institutions (Figure). 
The odds ratio for a claim to be accepted following a hip arthro-
plasty performed at a low-volume institution was 1.6 (95% CI 
1.1–2.5) compared with higher volume institutions (Table 3).
Discussion
The main finding of the present study is that approximately 
1% of all patients undergoing THA between 2008 and 2018 
were granted compensation by NPE. The probability of being 
granted compensation claims due to a treatment error is 1.6 
times more likely if the procedure was performed in a low-
volume institution compared with institutions with higher 
volumes of THAs. We found a 1.6 times increased risk of suf-
fering a treatment error that led to accepted claims by NPE 
if the THA was performed in the lowest volume institutions 
compared with all other institutions. However, the proportion 
of accepted claims was not statistically significantly differ-
ent between the lowest volume institutions and the 2nd high-
est volume institutions. The 2nd highest quarter consists of 
8 institutions, including 4 large university clinics in Norway. 
These institutions typically treat high-risk patients and com-
plex primary and revision cases, whereas the highest volume 
institutions consist of specialized “production” institutions 
that treat a high volume of relatively low-risk patients. We 
believe this might explain why Q3 has a somewhat higher 
number of accepted claims, despite relatively large annual 
procedure volumes. 
Low institutional procedure volumes increase the risk of 
adverse outcomes following elective hip arthroplasty and 
revision surgery (Glassou et al. 2016, Mufarrih et al. 2019). 
Our study confirms that low-volume institutions also have a 
higher ratio of accepted claims compared with institutions 
with higher volumes of THAs. However, the risk of ending up 
with compensation after a hip arthroplasty is only moderately 
elevated for the lowest volume institutions, with an odds ratio 
of 1.6 and a 95% confidence interval approaching 1.0. In con-
trast, in a similar study on compensation claims following total 
knee arthroplasty (TKA), we found a 3-fold increased risk of 
accepted claims in the lowest volume institutions (Randsborg 
et al. 2020). The effect of institutional volume on accepted 
claims seems to be much more pronounced for TKAs than 
for THAs as this is also found in a Finnish report (Järvelin 
et al. 2012). This is not surprising, since hospital volume has 
a greater effect on adverse outcome following knee arthro-
plasties compared with hip arthroplasties (Katz et al. 2004, 
Shervin et al. 2007). THA is indisputable a more successful 
procedure with higher patient satisfaction and less compli-
cations compared to TKA (Bourne et al. 2010), which may 
explain why institutional volume seems to have less impact on 
Table 2. Reasons for claims (n = 595) accepted 
by the Norwegian System of Patient Injury 
Compensation for treatment injuries follow-
ing total hip arthroplasty during 2008–2018
Reason for accepted claims n (%)
Hospital-acquired infection 201 (34)
Malposition of implant 67 (11)
Treatment failure 50 (8.4)
Anisomelia 50 (8.5)
Nerve injury 45 (7.6)
Aseptic loosening a 35 (5.9)
Abductor deficiency 33 (5.5)
Exception clause 30 (5.0)
Perioperative fracture 21 (3.5)
Technical error 17 (2.9)
Delayed treatment 16 (2.7)
Wrong indication 11 (1.8)
Pain 7 (1.2)
Component failure 4 (0.7)
Delayed diagnosis 3 (0.5)
Artery injury 2 (0.3)
Lack of information 2 (0.3)
Anesthesia 1 (0.2)
a Within 3 years.
Table 3. Likelihood of accepted claims from 
the Norwegian System of Patient Injury Com-
pensation during 2008–2018 by annual proce-
dure volume divided by quartiles into quarters
Quarter (Q) Odds ratio (95% CI)
Q1 vs. all other  1.6 (1.1–2.5)
Q1 vs. Q2 1.8 (1.1–3.0)
Q1 vs. Q3 1.4 (0.9–2.2)
Q1 vs. Q4 1.7 (1.1–2.7)
Q2 vs. Q3 0.8 (0.6–1.0)
Q2 vs. Q4 0.9 (0.7–1.2)
Q3 vs. Q4 1.2 (1.0–1.5)
Q1, Quarter 1 (< 93 annual procedures); 
Q2, Quarter 2 (93–263 annual procedures);
Q3, Quarter 3 (264–466 annual procedures); 






p = 0.8 p = 0.9
Procedure volume quarters







Proportion of accepted claims (%)
Proportion of accepted claims by number 
of surgeries stratified by annual hospital 
procedure volume. The 4 categories repre-
sent quarters, see Table 3. P-values derived 
from ANOVA adjusted with Tukey’s compar-
ison test.
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compensation after hip arthroplasties than after knee arthro-
plasties.
The dominant reason for accepted claims was hospital-
acquired infection, accounting for one-third of accepted 
claims. Hospital-acquired infection of an arthroplasty leads to 
prolonged hospitalization, and increased morbidity and mor-
tality, with extensive costs to the society (Senard et al. 2019). 
This is a reminder that all parties involved in arthroplasty sur-
gery should strive to reduce the risk of infection. 
The exception clause grants compensation to patients who 
suffer from infection following joint replacement, even when 
no treatment error has been identified. A similar decision has 
been made for early (within 3 years) aseptic loosening. It is a 
pragmatic policy in a no-blame compensation system. How-
ever, not all infections will automatically lead to compensa-
tion. All claims are reviewed independently. Patients with 
comorbidity, high infection risk, and poor compliance may not 
be granted compensation if infection occur. 
Other leading causes for accepted claims were wrong 
implant position, treatment failure (no further explanation was 
given), anisomelia, and nerve injury. 
Abductor deficiency was registered in 6% of accepted claims. 
This is likely related to the surgical technique and the direct 
lateral approach to the hip joint (Amlie et al. 2014, Winther et 
al. 2016). This approach has decreased substantially in com-
parison with posterior and anterior approaches in Norway in 
recent years and is now performed in less than 5% of all THAs 
(NAR 2020). We believe this explains the decline in claims due 
to abductor deficiency registered at the end of the study period.
Pain was a common reason for claim (Table 1). NPE reg-
istered 215 claims due to pain, although only 7 (3%) were 
accepted for compensation; pain alone does not serve as a 
cause for compensation, which is in line with previous reports 
from NPE (Clementsen et al. 2018, Randsborg et al. 2018, Aae 
et al. 2020).
Khan et al. (2020) assessed compensation claims based on 
the Danish arthroplasty register and found that 2.5% of all 
THAs filed a claim, which is somewhat higher than our find-
ings of 1.9%. They reported nerve damage and insufficient or 
incorrect treatment as the leading causes for accepted claims. 
Half of the claims were accepted, which is similar to the 44% 
of claims accepted in our study. In contrast to our study, they 
did not include revision surgery. Our study also adds knowl-
edge on accepted claims based on institutional volumes of 
THA, a topic that has received little attention in the literature. 
Bhutta et al. (2011) reviewed compensation claims after 
hip and knee arthroplasties over a 5-year period in the United 
Kingdom. THAs due to trauma and revision surgery were 
excluded. They identified 271 claims that had reached a con-
clusion, where 109 (40%) resulted in payouts. Nerve injury, 
surgeon error, and pain were the 3 most common causes 
for claims. Our material contains 5 times as many claims as 
Bhutta et al. and includes revision surgery. Albeit nerve injury 
and surgeon error are common reasons for accepted claims 
in both studies, infection was far more common in our study. 
This discrepancy is likely caused by the exception clause in 
the Scandinavian compensation systems that grants compen-
sation after infection even if no treatment error is identified. 
This is supported by a study on patient claims following pros-
thetic hip infections in Sweden, which found that 329 of 441 
(75%) of claims were accepted (Kasina et al. 2018), which 
is the same as the 209 of 275 (76%) of infections that were 
accepted in our study. 
2 studies from the United States analyzed malpractice law-
suits after THA and both identified substantially fewer claims 
than our study, which may relate to the systems (Bokshan et 
al. 2017, Samuel et al. 2019). In Norway, filing a complaint 
for compensation is free of charge and easily done online. 
Additionally, the system is a no-fault system with claims not 
directed at individual surgeons or institutions, and surgeons 
are required by law in case of complications to inform patients 
how to apply for compensation. In the United States, filing a 
complaint will normally require legal representation, which 
might constitute a higher threshold for filing a claim.
Some treatment errors found in our study are avoidable or 
at least modifiable with adjustments in medical practice. This 
is coherent with findings from Sweden, which stated that 49% 
of THA patients suffered an adverse advent that could have 
been prevented (Magnéli et al. 2020). Delayed diagnosis or 
treatment and erroneous indications have previously been 
identified as avoidable causes for compensation (Clementsen 
et al. 2018, Randsborg et al. 2018, Aae et al. 2020). During the 
study period, all hospitals in Norway implemented the use of 
the safe surgery protocol initiated by the World Health Orga-
nization (WHO 2020). No cases of wrong-sided surgery were 
identified in our study and this may relate to the implementa-
tion of these guidelines. 
1 accepted claim was not due to the surgery itself, but to 
anesthesia and is a reminder that arthroplasty carries risks not 
directly related to the surgery. 
This study has limitations. Any mislabeling of procedures 
may lead to some patients not being included in the study. 
NPE does not cover all possible complications following 
THA, and it is likely that some patients have experienced a 
complication due to a treatment error that would lead to com-
pensation, but never filed a claim. These factors may induce 
biases to the database used in this study.
The data originates from 1 country using the principle of 
no-blame, which may reduce the generalizability of the study. 
However, the purpose of this study is to evaluate compensa-
tion claims to identify areas for potential improvement in our 
patient care, which is likely of universal interest. 
In conclusion, the main reasons for compensation were a 
hospital-acquired infection and malposition of the implant. The 
findings suggest that small-volume institutions should consider 
increasing the volume of THAs or referring these patients to 
higher volume institutions. Several complications identified 
are reducible with adjustments to current clinical practice.
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